Monogram Orthopaedics, Inc. (NASDAQ: MGRM) was given a new $5.40 price target on by analysts at Roth Capital.
Monogram Orthopaedics, Inc. (NASDAQ: MGRM) had its price target raised by analysts at Roth Mkm from $4.00 to $5.40. They now have a "buy" rating on the stock.
FDA 510(k) Clearance Already Has This Micro Cap Off To The Races [Globe and Mail, The (Toronto, Canada)]